PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes or young patients. Part of a set of translational phase II trials based on molecular subtypes

Trial Profile

PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes or young patients. Part of a set of translational phase II trials based on molecular subtypes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Letrozole; Paclitaxel; Tamoxifen
  • Indications Breast cancer; Male breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PREDIX LumB
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Feb 2016 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024 as reported by ClinicalTrials.gov record.
    • 14 Feb 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top